Cardiovascular drugs refer to prescription drugs and drugs for diseases related to the structure and function of the heart and blood vessels and diseases such as heart failure, coronary artery disease, high cholesterol, blood clots, traffic and other disorders.
These diseases are associated with the circulatory system and the heart. Cardiovascular diseases such as rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease and cerebrovascular heart disease. High blood pressure causes hypertensive heart disease. The main concerns with hypertensive heart disease are enlargement, heart failure, angina, and coronary heart disease. The blood vessels of the brain are affected by cerebrovascular diseases. Common types of cerebrovascular disease are stroke, vascular dementia, transient ischemic attacks, and subarachnoid hemorrhage.
The cardiovascular drugs market includes the sales of cardiovascular drugs by entities (organizations, sole proprietorships, and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce antihypertensive drugs to prevent heart failure by controlling blood pressure and lipid-lowering drugs that reduce lipid and lipoprotein levels in the blood. It also includes establishments that produce antithrombotic drugs to treat arterial and venous thrombosis.
The cardiovascular drugs market is segmented into antihypertensive drugs; hypolipidemic; antithrombotic; and other drugs for cardiovascular diseases (congestive heart failure, antiarrhythmic and antianginal drugs). The global market for cardiovascular drugs is expected to grow from $87.79 billion in 2020 to $92.41 billion in 2021 at a compound annual growth rate (CAGR) of 5.3%. The growth is mainly due to companies reorganizing their operations and recovering from the impact of COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of business activities that resulted in operational challenges. The market is expected to reach $107.77 billion in 2025 with a CAGR of 4%.
Asia-Pacific was the largest region in the global cardiovascular drug market, accounting for 40% of the market in 2020. North America was the second largest region, accounting for 27% of the global cardiovascular drug market. Africa was the smallest region in the global cardiovascular drug market.
Rising sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world’s population, particularly non-communicable diseases such as cancer, diabetes and cardiovascular disease. Long working hours, less physical activity, and poor eating and drinking habits are major causes of cardiovascular disease, including hypertension. According to the World Health Organization, the prevalence of chronic diseases is currently increasing by 57% worldwide. These factors are expected to increase the number of patients globally, thereby driving the cardiovascular drugs market over the forecast period.
Major players dominating the global cardiovascular disease drug market are Pfizer, Inc., AstraZeneca plc, Merck & Co., Sanofi SA, Novartis AG, Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited, and Bayer AG. Other key players influencing the global cardiovascular disease drug market are Astellas Pharma Inc., Boehringer Ingelheim GmbH, United Therapeutics Corporation, Johnson & Johnson, Roche Holding AG, and Actelion Pharmaceuticals Ltd.
